Physician profile
Gerard Mcnulty
NPI 1073592945
$26,872.33
in general payments reported to CMS, 2019-2025
63 companies · $4,015 in 2025
The $4,015 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,334 · 2020: $3,352 · 2021: $3,988 · 2022: $3,221 · 2023: $4,142 · 2024: $4,821 · 2025: $4,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,978.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,786.52 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $2,687.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,020.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,773.60 | 2019-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $1,730.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,508.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,296.47 | 2019-2025 | |
| Amgen INC. | $888.00 | 2019-2025 | Evenity, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $883.19 | 2019-2025 | Xarelto, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $706.83 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $667.48 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $661.90 | 2019-2025 | Rexulti |
| Lundbeck LLC | $653.81 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $586.05 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Axsome Therapeutics, INC. | $546.14 | 2023-2025 | Auvelity, Sunosi, Symbravo |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Mcnulty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.